Efficacy and safety of PD-1/CTLA-4 bispecific antibody in the treatment of gynecological malignant tumor
Objective To analyze the blood routine,imaging and other related data of gynecological malignant tumor patients treated with PD-1/CTLA-4 bispecific antibody,and evaluate the effectiveness and safety of the drug in the treatment of gynecological malignant tumor patients.Methods 22 patients with gynecological malignant tumors were selected,all of whom received bispecific antibodies against programmed cell death protein-1(PD-1)/targeted cytotoxic T lymphocyte associated antigen-4(CTLA-4)with or without chemotherapy or targeted therapy.The recent efficacy and incidence of adverse reactions were observed.Results There were 4 cases of CR,accounting for 18.2%,2 cases of PR,accounting for 9.1%,6 cases of SD,accounting for 27.3%.The total clinical effective rate was 27.3%(CR+PR),with a clinical benefit rate of 54.5%(CR+PR+SD).There were 10 cases of PD,accounting for 45.5%.Follow-up to October 2023 showed that 14 patients were alive,accounting for 63.6%,and 8 patients were dead,accounting for 36.4%.The incidence of treatment-related adverse events(TRAEs)was 95.5%(21/22).The incidence of severe adverse reactions was 50.0%(11/22).The incidence of hemoglobin decrease above grade 3 was 9.1%(2/22),the incidence of leukopenia decrease above grade 3 was 27.3%(6/22),the incidence of neutropenia decrease above grade 3 was 13.6%(3/22),and the incidence of ALT and AST increase above grade 3 was 4.5%(1/22).Among them,the severe adverse reactions related to immunotherapy were:the incidence of severe hemoglobin reduction was 4.5%(1/22),the incidence of severe platelet reduction was 4.5%(1/22),and the incidence of severe liver function impairment was 4.5%(1/22).Conclusion The application of PD-1/CTLA-4 bispecific antibody in the treatment of advanced/recurrent gynecological malignant tumor has a high clinical benefit rate and a low incidence of severe adverse reactions,which has a high promotion value.
万方数据
维普
